This early-stage trial tests a new treatment called RNDP-001, which involves transplanting dopamine-producing stem cells into the brains of 12 people with Parkinson's disease. The main goal is to see if the procedure is safe and tolerable. Researchers will also monitor changes in…
Phase: PHASE1, PHASE2 • Sponsor: Kenai Therapeutics • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC